Literature DB >> 15261432

Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance.

Sara Orecchia1, Francesca Schillaci, Michela Salvio, Roberta Libener, Pier-Giacomo Betta.   

Abstract

Cadherins and their associated cytoplasmic proteins, catenins, are critical to the maintenance of normal tissue integrity and the suppression of cancer invasion. The cadherin profile in malignant mesothelioma (MM) is not well defined and the role of the cadherin-catenin system in the pathogenesis of MM remains to be determined. By means of Western blot analysis and immunohistochemistry the expression of E (epithelial)-, N (neural)-, P (placental)-cadherin, and alpha-, beta- and gamma-catenins was studied in nine human MM cell lines and five human mesothelial cell lines. Mesothelial cells consistently expressed only N-cadherin and alpha- and beta-catenins. All but one MM cell line were N-cadherin-positive and all of them were also positive for alpha- and beta-catenins. E-cadherin was found in six (66.7%) and gamma-catenin in seven (77.8%) MM cell lines. Five of these E-cadherin-positive lines co-expressed N-cadherin and the remaining one was also P-cadherin-positive. Double immunofluorescence staining revealed the plasma membrane co-localisation of both cadherin types in MM cell lines that co-expressed E- and N-cadherin or E- and P-cadherin, respectively. Immunoprecipitation showed complexes of beta-catenin with both cadherin types when co-expressed. The results point to upregulation of E-cadherin and gamma-catenin in most MM cases and demonstrate that cadherin expression is more heterogeneous and less mutually exclusive in MM compared with the mesothelium, although the biological significance of this finding remains unclear.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261432     DOI: 10.1016/j.lungcan.2004.04.027

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1.

Authors:  Stefano Grosso; Elisa Pesce; Daniela Brina; Anne Beugnet; Fabrizio Loreni; Stefano Biffo
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

2.  CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.

Authors:  Erika Ortolan; Alice Giacomino; Francesca Martinetto; Simona Morone; Nicola Lo Buono; Enza Ferrero; Giorgio Scagliotti; Silvia Novello; Sara Orecchia; Enrico Ruffini; Ida Rapa; Luisella Righi; Marco Volante; Ada Funaro
Journal:  Oncotarget       Date:  2014-08-15

3.  Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes.

Authors:  Mauro Ravera; Elisabetta Gabano; Ilaria Zanellato; Elena Perin; Aldo Arrais; Domenico Osella
Journal:  Bioinorg Chem Appl       Date:  2016-09-28       Impact factor: 7.778

4.  Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Authors:  Fabio Bozzi; Silvia Brich; Gian Paolo Dagrada; Tiziana Negri; Elena Conca; Barbara Cortelazzi; Antonino Belfiore; Federica Perrone; Ambra Vittoria Gualeni; Annunziata Gloghini; Antonello Cabras; Monica Brenca; Roberta Maestro; Nadia Zaffaroni; Paolo Casali; Rossella Bertulli; Marcello Deraco; Silvana Pilotti
Journal:  Oncotarget       Date:  2016-11-15

5.  Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Authors:  Stefania Augeri; Stefania Capano; Simona Morone; Giulia Fissolo; Alice Giacomino; Silvia Peola; Zahida Drace; Ida Rapa; Silvia Novello; Marco Volante; Luisella Righi; Enza Ferrero; Erika Ortolan; Ada Funaro
Journal:  Oncotarget       Date:  2018-04-27

6.  A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma.

Authors:  Stefania Oliveto; Roberta Alfieri; Annarita Miluzio; Alessandra Scagliola; Raissa S Secli; Pierluigi Gasparini; Stefano Grosso; Luciano Cascione; Luciano Mutti; Stefano Biffo
Journal:  Cancer Res       Date:  2018-08-02       Impact factor: 12.701

7.  Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.

Authors:  Viviana Volta; Elia Ranzato; Simona Martinotti; Simone Gallo; Maria Veronica Russo; Luciano Mutti; Stefano Biffo; Bruno Burlando
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

8.  The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Authors:  Ymera Pignochino; Carmine Dell'Aglio; Simona Inghilleri; Michele Zorzetto; Marco Basiricò; Federica Capozzi; Marta Canta; Davide Piloni; Francesca Cemmi; Dario Sangiolo; Loretta Gammaitoni; Marco Soster; Serena Marchiò; Ernesto Pozzi; Patrizia Morbini; Maurizio Luisetti; Massimo Aglietta; Giovanni Grignani; Giulia M Stella
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

9.  Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening.

Authors:  Elia Ranzato; Simona Martinotti; Valeria Magnelli; Bruno Murer; Stefano Biffo; Luciano Mutti; Bruno Burlando
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

Review 10.  Use of preclinical models for malignant pleural mesothelioma.

Authors:  Marie Shamseddin; Joanna Obacz; Mathew J Garnett; Robert Campbell Rintoul; Hayley Elizabeth Francies; Stefan John Marciniak
Journal:  Thorax       Date:  2021-03-10       Impact factor: 9.139

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.